{"database": "lobbying", "table": "lobbying_activities", "rows": [[2267173, "0bf954e1-7e54-4ecb-a45c-9403fca00c7d", "Q1", "AMERICAN PHARMACISTS ASSOCIATION", 3071, "AMERICAN PHARMACISTS ASSOCIATION", 2019, "first_quarter", "CSP", "S. 61 - Safe and Affordable Drugs from Canada Act of 2019\nH.R. 447 - Affordable and Safe Prescription Drug Importation Act\nS. 97 - Affordable and Safe Prescription Drug Importation Act\nH.R. - BLOCKING Act of 2019; To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval", "HOUSE OF REPRESENTATIVES,SENATE", 0, 0, "2019-04-16T12:37:39.127000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2267173"], "units": {}, "query_ms": 9.992536972276866, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}